Transactivation of genes encoding for phase II enzymes and phase III transporters by phytochemical antioxidants

Molecules

Volumn 15, Issue 9, 2010, Pages 6332-6348

  Yang, Yoon Mee ^a   Noh, Kyoung ^a   Han, Chang Yeob ^a   Kim, Sang Geon ^a  

^a Seoul National University   (South Korea)

Author keywords

CCAAT enhancer binding protein ; Farnesoid X receptor; Hepatic nuclear factor; NF E2 related factor 2; Phase 2 enzyme; Phase 3 transporter

Indexed keywords

ANTIOXIDANT; CARRIER PROTEIN; ENZYME; XENOBIOTIC AGENT;

DRUG DETOXIFICATION; DRUG EFFECT; GENETICS; METABOLISM; REVIEW; TRANSCRIPTION INITIATION;

ANTIOXIDANTS; ENZYMES; MEMBRANE TRANSPORT PROTEINS; METABOLIC DETOXICATION, DRUG; TRANSCRIPTIONAL ACTIVATION; XENOBIOTICS;

EID: 77957298139     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules15096332     Document Type: Review

References (106)

1. Rushmore, T. H.; Kong, A. N. Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr. Drug Metab. 2002, 3, 481-490.
2. Wang, H.; Le Cluyse, E. L. Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin. Pharmacokinet. 2003, 42, 1331-1357.
3. Mates, J. M. Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. Toxicology 2000, 153, 83-104.
4. Mizuno, N.; Niwa, T.; Yotsumoto, Y.; Sugiyama, Y. Impact of drug transporter studies on drug discovery and development. Pharmacol. Rev. 2003, 55, 425-461.
5. Staudinger, J. L.; Madan, A.; Carol, K. M.; Parkinson, A. Regulation of drug transporter gene expression by nuclear receptors. Drug Metab. Dispos. 2003, 31, 523-527.
6. Dean, M.; Hamon, Y.; Chimini, G. The human ATP-binding cassette (ABC) transporter superfamily. J. Lipid Res. 2001, 42, 1007-1017. (Pubitemid 32645780)
7. Kerb, R.; Hoffmeyer, S.; Brinkmann, U. ABC drug transporters: Hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2001, 2, 51-64.
8. Brinkmann, U.; Eichelbaum, M. Polymorphisms in the ABC drug transporter gene MDR1. Pharmacogenomics J. 2001, 1, 59-64.
9. Reichel, C.; Gao, B.; Van Montfoort, J.; Cattori, V.; Rahner, C.; Hagenbuch, B.; Stieger, B.; Kamisako, T.; Meier, P. J. Localization and function of the organic anion-transporting polypeptide Oatp2 in rat liver. Gastroenterology 1999, 117, 688-695.
10. Shitara, Y.; Sugiyama, D.; Kusuhara, H.; Kato, Y.; Abe, T.; Meier, P. J.; Itoh, T.; Sugiyama, Y. Comparative inhibitory effects of different compounds on rat oatpl (slc21a1) - and Oatp2 (Slc21a5)-mediated transport. Pharm. Res. 2002, 19, 147-153.
11. Kim, R. B. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur. J. Clin. Invest. 2003, 33(Suppl. 2), 1-5.
12. Itoh, K.; Ishii, T.; Wakabayashi, N.; Yamamoto, M. Regulatory mechanisms of cellular response to oxidative stress. Free Radical Res. 1999, 31, 319-324.
13. Motohashi, H.; Yamamoto, M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol. Med. 2004, 10, 549-557.
14. Li, W.; Kong, A. N. Molecular mechanisms of Nrf2-mediated antioxidant response. Mol. Carcinog. 2009, 48, 91-104.
15. Eggler, A. L.; Gay, K. A.; Mesecar, A. D. Molecular mechanisms of natural products in chemoprevention: Induction of cytoprotective enzymes by Nrf2. Mol. Nutr. Food Res. 2008, 52(Suppl 1), S84-S94.
16. Ramji, D. P.; Foka, P. CCAAT/enhancer-binding proteins: Structure, function and regulation. Biochem. J. 2002, 365, 561-575.
17. Buck, M.; Chojkier, M. Signal transduction in the liver: C/EBPbeta modulates cell proliferation and survival. Hepatology 2003, 37, 731-738.
18. Kang, K. W.; Cho, I. J.; Lee, C. H.; Kim, S. G. Essential role of phosphatidylinositol 3-kinasedependent CCAAT/enhancer binding protein beta activation in the induction of glutathione S-transferase by oltipraz. J. Natl. Cancer Inst. 2003, 95, 53-66.
19. Sprott, K. M.; Chumley, M. J.; Hanson, J. M.; Dobrowsky, R. T. Decreased activity and enhanced nuclear export of CCAAT-enhancer-binding protein beta during inhibition of adipogenesis by ceramide. Biochem. J. 2002, 365, 181-191.
20. Ki, S. H.; Kim, S. G. Phase II enzyme induction by alpha-lipoic acid through phosphatidylinositol 3-kinase-dependent C/EBPs activation. Xenobiotica 2008, 38, 587-604.
21. Park, E. Y.; Cho, I. J.; Kim, S. G. Transactivation of the PPAR-responsive enhancer module in chemopreventive glutathione S-transferase gene by the peroxisome proliferator-activated receptor-gamma and retinoid X receptor heterodimer. Cancer Res. 2004, 64, 3701-3713.
22. Schrem, H.; Klempnauer, J.; Borlak, J. Liver-enriched transcription factors in liver function and development. Part I: The hepatocyte nuclear factor network and liver-specific gene expression. Pharmacol. Rev. 2002, 54, 129-158.
23. Parrizas, M.; Maestro, M. A.; Boj, S. F.; Paniagua, A.; Casamitjana, R.; Gomis, R.; Rivera, F.; Ferrer, J. Hepatic nuclear factor 1-alpha directs nucleosomal hyperacetylation to its tissue-specific transcriptional targets. Mol. Cell Biol. 2001, 21, 3234-3243.
24. Borlak, J.; Thum, T. Induction of nuclear transcription factors, cytochrome P450 monooxygenases, and glutathione S-transferase alpha gene expression in Aroclor 1254-treated rat hepatocyte cultures. Biochem. Pharmacol. 2001, 61, 145-153.
25. Pontoglio, M.; Barra, J.; Hadchouel, M.; Doyen, A.; Kress, C.; Bach, J. P.; Babinet, C.; Yaniv, M. Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 1996, 84, 575-585.
26. Wobser, H.; Dussmann, H.; Kogel, D.; Wang, H.; Reimertz, C.; Wollheim, C. B.; Byrne, M. M.; Prehn, J. H. Dominant-negative suppression of HNF-1 alpha results in mitochondrial dysfunction, INS-1 cell apoptosis, and increased sensitivity to ceramide-, but not to high glucose-induced cell death. J. Biol. Chem. 2002, 277, 6413-6421.
27. Park, I. N.; Cho, I. J.; Kim, S. G. Ceramide, an apoptotic rheostat, inhibits CCAAT/enhancer binding protein-beta and NF-E2-related factor-2 activation: The role in glutathione S-transferase A2 gene repression. Drug Metab. Dispos. 2004, 32, 893-897.
28. Rushmore, T. H.; King, R. G.; Paulson, K. E.; Pickett, C. B. Regulation of glutathione S-transferase Ya subunit gene expression: Identification of a unique xenobiotic-responsive element controlling inducible expression by planar aromatic compounds. Proc. Natl. Acad. Sci. USA 1990, 87, 3826-3830.
29. Maher, J. M.; Slitt, A. L.; Callaghan, T. N.; Cheng, X.; Cheung, C.; Gonzalez, F. J.; Klaassen, C. D. Alterations in transporter expression in liver, kidney, and duodenum after targeted disruption of the transcription factor HNF1alpha. Biochem. Pharmacol. 2006, 72, 512-522.
30. Hayhurst, G. P.; Lee, Y. H.; Lambert, G.; Ward, J. M.; Gonzalez, F. J. Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol. Cell Biol. 2001, 21, 1393-1403.
31. Watt, A. J.; Garrison, W. D.; Duncan, S. A. HNF4: A central regulator of hepatocyte differentiation and function. Hepatology 2003, 37, 1249-1253.
32. Barbier, O.; Girard, H.; Inoue, Y.; Duez, H.; Villeneuve, L.; Kamiya, A.; Fruchart, J. C.; Guillemette, C.; Gonzalez, F. J.; Staels, B. Hepatic expression of the UGT1A9 gene is governed by hepatocyte nuclear factor 4alpha. Mol. Pharmacol. 2005, 67, 241-249.
33. Echchgadda, I.; Song, C. S.; Oh, T.; Ahmed, M.; De La Cruz, I. J.; Chatterjee, B. The xenobioticsensing nuclear receptors pregnane X receptor, constitutive androstane receptor, and orphan nuclear receptor hepatocyte nuclear factor 4alpha in the regulation of human steroid-/bile acidsulfotransferase. Mol. Endocrinol. 2007, 21, 2099-2111.
34. Dietrich, C. G.; Martin, I. V.; Porn, A. C.; Voigt, S.; Gartung, C.; Trautwein, C.; Geier, A. Fasting induces basolateral uptake transporters of the SLC family in the liver via HNF4alpha and PGC1alpha. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 293, G585-G590.
35. Gervois, P.; Torra, I. P.; Fruchart, J. C.; Staels, B. Regulation of lipid and lipoprotein metabolism by PPAR activators. Clin. Chem. Lab. Med. 2000, 38, 3-11.
36. Gilde, A. J.; van der Lee, K. A.; Willemsen, P. H.; Chinetti, G.; van der Leij, F. R.; van der Vusse, G. J.; Staels, B.; van Bilsen, M. Peroxisome proliferator-activated receptor (PPAR) alpha and PPARbeta/delta, but not PPARgamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ. Res. 2003, 92, 518-524.
37. Issemann, I.; Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347, 645-650.
38. Tugwood, J. D.; Issemann, I.; Anderson, R. G.; Bundell, K. R.; McPheat, W. L.; Green, S. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. EMBO J. 1992, 11, 433-439.
39. Johnson, B. M.; Charman, W. N.; Porter, C. J. Application of compartmental modeling to an examination of in vitro intestinal permeability data: Assessing the impact of tissue uptake, P-glycoprotein, and CYP3A. Drug Metab. Dispos. 2003, 31, 1151-1160.
40. Perloff, M. D.; von Moltke, L. L.; Greenblatt, D. J. Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats. Xenobiotica 2004, 34, 133-150.
41. Kullak-Ublick, G. A.; Becker, M. B. Regulation of drug and bile salt transporters in liver and intestine. Drug Metab. Rev. 2003, 35, 305-317.
42. Song, X.; Xie, M.; Zhang, H.; Li, Y.; Sachdeva, K.; Yan, B. The pregnane X receptor binds to response elements in a genomic context-dependent manner, and PXR activator rifampicin selectively alters the binding among target genes. Drug Metab. Dispos. 2004, 32, 35-42.
43. Geick, A.; Eichelbaum, M.; Burk, O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 2001, 276, 14581-14587.
44. Staudinger, J.; Liu, Y.; Madan, A.; Habeebu, S.; Klaassen, C. D. Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metab Dispos 2001, 29, 1467-1472.
45. Staudinger, J. L.; Goodwin, B.; Jones, S. A.; Hawkins-Brown, D.; MacKenzie, K. I.; La Tour, A.; Liu, Y.; Klaassen, C. D.; Brown, K. K.; Reinhard, J.; Willson, T. M.; Koller, B. H.; Kliewer, S. A. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. USA 2001, 98, 3369-3374.
46. Kast, H. R.; Goodwin, B.; Tarr, P. T.; Jones, S. A.; Anisfeld, A. M.; Stoltz, C. M.; Tontonoz, P.; Kliewer, S.; Willson, T. M.; Edwards, P. A. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J. Biol. Chem. 2002, 277, 2908-2915.
47. Kullak-Ublick, G. A.; Stieger, B.; Meier, P. J. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 2004, 126, 322-342. (Pubitemid 38040747)
48. Teng, S.; Jekerle, V.; Piquette-Miller, M. Induction of ABCC3 (MRP3) by pregnane X receptor activators. Drug Metab. Dispos. 2003, 31, 1296-1299.
49. Forman, B. M.; Goode, E.; Chen, J.; Oro, A. E.; Bradley, D. J.; Perlmann, T.; Noonan, D. J.; Burka, L. T.; McMorris, T.; Lamph, W. W.; Evans, R. M.; Weinberger, C. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995, 81, 687-693.
50. Huber, R. M.; Murphy, K.; Miao, B.; Link, J. R.; Cunningham, M. R.; Rupar, M. J.; Gunyuzlu, P. L.; Haws, T. F.; Kassam, A.; Powell, F.; Hollis, G. F.; Young, P. R.; Mukherjee, R.; Burn, T. C. Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters. Gene 2002, 290, 35-43.
51. Zhang, Y.; Kast-Woelbern, H. R.; Edwards, P. A. Natural structural variants of the nuclear receptor farnesoid X receptor affect transcriptional activation. J. Biol. Chem. 2003, 278, 104-110.
52. Wang, H.; Chen, J.; Hollister, K.; Sowers, L. C.; Forman, B. M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 1999, 3, 543-553.
53. Lee, F. Y.; Lee, H.; Hubbert, M. L.; Edwards, P. A.; Zhang, Y. FXR, a multipurpose nuclear receptor. Trends Biochem. Sci. 2006, 31, 572-580.
54. Kalaany, N. Y.; Mangelsdorf, D. J. LXRS and FXR: The yin and yang of cholesterol and fat metabolism. Annu. Rev. Physiol. 2006, 68, 159-191.
55. Engelman, J. A.; Luo, J.; Cantley, L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006, 7, 606-619.
56. Lee, J. M.; Hanson, J. M.; Chu, W. A.; Johnson, J. A. Phosphatidylinositol 3-kinase, not extracellular signal-regulated kinase, regulates activation of the antioxidant-responsive element in IMR-32 human neuroblastoma cells. J. Biol. Chem. 2001, 276, 20011-20016.
57. Kang, K. W.; Lee, S. J.; Park, J. W.; Kim, S. G. Phosphatidylinositol 3-kinase regulates nuclear translocation of NF-E2-related factor 2 through actin rearrangement in response to oxidative stress. Mol. Pharmacol. 2002, 62, 1001-1010.
58. Hyde, R.; Hajduch, E.; Powell, D. J.; Taylor, P. M.; Hundal, H. S. Ceramide down-regulates System A amino acid transport and protein synthesis in rat skeletal muscle cells. FASEB J. 2005, 19, 461-463.
59. Park, I. N.; Cho, I. J.; Kim, S. G. Ceramide negatively regulates glutathione S-transferase gene transactivation via repression of hepatic nuclear factor-1 that is degraded by the ubiquitin proteasome system. Mol. Pharmacol. 2004, 65, 1475-1484.
60. Sekine, O.; Nishio, Y.; Egawa, K.; Nakamura, T.; Maegawa, H.; Kashiwagi, A. Insulin activates CCAAT/enhancer binding proteins and proinflammatory gene expression through the phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells. J. Biol. Chem. 2002, 277, 36631-36639.
61. Ko, M. S.; Lee, S. J.; Kim, J. W.; Lim, J. W.; Kim, S. G. Differential effects of the oxidized metabolites of oltipraz on the activation of CCAAT/enhancer binding protein-beta and NF-E2-related factor-2 for GSTA2 gene induction. Drug Metab. Dispos. 2006, 34, 1353-1360.
62. Nakanishi, H.; Brewer, K. A.; Exton, J. H. Activation of the zeta isozyme of protein kinase C by phosphatidylinositol 3, 4, 5-trisphosphate. J. Biol. Chem. 1993, 268, 13-16.
63. Huang, H. C.; Nguyen, T.; Pickett, C. B. Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J. Biol. Chem. 2002, 277, 42769-42774.
64. Li, B.; Wang, X.; Rasheed, N.; Hu, Y.; Boast, S.; Ishii, T.; Nakayama, K.; Nakayama, K. I.; Goff, S. P. Distinct roles of c-Abl and Atm in oxidative stress response are mediated by protein kinase C delta. Genes Dev. 2004, 18, 1824-1837.
65. Gineste, R.; Sirvent, A.; Paumelle, R.; Helleboid, S.; Aquilina, A.; Darteil, R.; Hum, D. W.; Fruchart, J. C.; Staels, B. Phosphorylation of farnesoid X receptor by protein kinase C promotes its transcriptional activity. Mol. Endocrinol. 2008, 22, 2433-2447.
66. Frankenberg, T.; Miloh, T.; Chen, F. Y.; Ananthanarayanan, M.; Sun, A. Q.; Balasubramaniyan, N.; Arias, I.; Setchell, K. D.; Suchy, F. J.; Shneider, B. L. The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor. Hepatology 2008, 48, 1896-1905.
67. Yu, R.; Chen, C.; Mo, Y. Y.; Hebbar, V.; Owuor, E. D.; Tan, T. H.; Kong, A. N. Activation of mitogen-activated protein kinase pathways induces antioxidant response element-mediated gene expression via a Nrf2-dependent mechanism. J. Biol. Chem. 2000, 275, 39907-39913.
68. Keum, Y. S.; Owuor, E. D.; Kim, B. R.; Hu, R.; Kong, A. N. Involvement of Nrf2 and JNK1 in the activation of antioxidant responsive element (ARE) by chemopreventive agent phenethyl isothiocyanate (PEITC). Pharm. Res. 2003, 20, 1351-1356.
69. Shen, G.; Hebbar, V.; Nair, S.; Xu, C.; Li, W.; Lin, W.; Keum, Y. S.; Han, J.; Gallo, M. A.; Kong, A. N. Regulation of Nrf2 transactivation domain activity. The differential effects of mitogenactivated protein kinase cascades and synergistic stimulatory effect of Raf and CREB-binding protein. J. Biol. Chem. 2004, 279, 23052-23060.
70. Yu, R.; Lei, W.; Mandlekar, S.; Weber, M. J.; Der, C. J.; Wu, J.; Kong, A. N. Role of a mitogenactivated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals. J. Biol. Chem. 1999, 274, 27545-27552.
71. Yu, R.; Mandlekar, S.; Lei, W.; Fahl, W. E.; Tan, T. H.; Kong, A. N. p38 mitogen-activated protein kinase negatively regulates the induction of phase II drug-metabolizing enzymes that detoxify carcinogens. J. Biol. Chem. 2000, 275, 2322-2327.
72. Roy, S. K.; Hu, J.; Meng, Q.; Xia, Y.; Shapiro, P. S.; Reddy, S. P.; Platanias, L. C.; Lindner, D. J.; Johnson, P. F.; Pritchard, C.; Pages, G.; Pouyssegur, J.; Kalvakolanu, D. V. MEKK1 plays a critical role in activating the transcription factor C/EBP-beta-dependent gene expression in response to IFN-gamma. Proc. Natl. Acad. Sci. USA 2002, 99, 7945-7950.
73. Salmenpera, P.; Hamalainen, S.; Hukkanen, M.; Kankuri, E. Interferon-gamma induces C/EBP beta expression and activity through MEK/ERK and p38 in T84 colon epithelial cells. Am. J. Physiol. Cell Physiol. 2003, 284, C1133-C1139.
74. Gomez-Santos, C.; Barrachina, M.; Gimenez-Xavier, P.; Dalfo, E.; Ferrer, I.; Ambrosio, S. Induction of C/EBP beta and GADD153 expression by dopamine in human neuroblastoma cells. Relationship with alpha-synuclein increase and cell damage. Brain Res. Bull. 2005, 65, 87-95.
75. Chiang, J. Y. Hepatocyte nuclear factor 4alpha regulation of bile acid and drug metabolism. Expert Opin. Drug Metab. Toxicol. 2009, 5, 137-147.
76. Han, S.; Li, T.; Ellis, E.; Strom, S.; Chiang, J. Y. A novel bile acid-activated vitamin D receptor signaling in human hepatocytes. Mol. Endocrinol. 2010, 24, 1151-1164.
77. Ktistaki, E.; Talianidis, I. Modulation of hepatic gene expression by hepatocyte nuclear factor 1. Science 1997, 277, 109-112.
78. Jung, D.; Kullak-Ublick, G. A. Hepatocyte nuclear factor 1 alpha: A key mediator of the effect of bile acids on gene expression. Hepatology 2003, 37, 622-631.
79. Wang, B.; Cai, S. R.; Gao, C.; Sladek, F. M.; Ponder, K. P. Lipopolysaccharide results in a marked decrease in hepatocyte nuclear factor 4 alpha in rat liver. Hepatology 2001, 34, 979-989.
80. Kuo, C. J.; Conley, P. B.; Chen, L.; Sladek, F. M.; Darnell, J. E., Jr.; Crabtree, G. R. A transcriptional hierarchy involved in mammalian cell-type specification. Nature 1992, 355, 457-461.
81. Moller, D. E.; Xia, C. H.; Tang, W.; Zhu, A. X.; Jakubowski, M. Human rsk isoforms: cloning and characterization of tissue-specific expression. Am. J. Physiol. 1994, 266, C351-359.
82. Zhao, Y.; Bjorbaek, C.; Moller, D. E. Regulation and interaction of pp90 (rsk) isoforms with mitogen-activated protein kinases. J. Biol. Chem. 1996, 271, 29773-29779.
83. Lee, S. J.; Kim, S. G. Role of p90 ribosomal S6-kinase-1 in oltipraz-induced specific phosphorylation of CCAAT/enhancer binding protein-beta for GSTA2 gene transactivation. Mol. Pharmacol. 2006, 69, 385-396.
84. Wiegand, H.; Wagner, A. E.; Boesch-Saadatmandi, C.; Kruse, H. P.; Kulling, S.; Rimbach, G. Effect of dietary genistein on Phase II and antioxidant enzymes in rat liver. Cancer Genomics Proteomics 2009, 6, 85-92.
85. Froyen, E. B.; Reeves, J. L.; Mitchell, A. E.; Steinberg, F. M. Regulation of phase II enzymes by genistein and daidzein in male and female Swiss Webster mice. J. Med. Food. 2009, 12, 1227-1237.
86. Hanet, N.; Lancon, A.; Delmas, D.; Jannin, B.; Chagnon, M. C.; Cherkaoui-Malki, M.; Latruffe, N.; Artur, Y.; Heydel, J. M. Effects of endocrine disruptors on genes associated with 17betaestradiol metabolism and excretion. Steroids 2008, 73, 1242-1251.
87. Chen, C. Y.; Jang, J. H.; Li, M. H.; Surh, Y. J. Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells. Biochem. Biophys. Res. Commun. 2005, 331, 993-1000.
88. Canistro, D.; Bonamassa, B.; Pozzetti, L.; Sapone, A.; Abdel-Rahman, S. Z.; Biagi, G. L.; Paolini, M. Alteration of xenobiotic metabolizing enzymes by resveratrol in liver and lung of CD1 mice. Food Chem. Toxicol. 2009, 47, 454-461.
89. Kweon, S. H.; Song, J. H.; Kim, T. S. Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression. Biochem. Biophys. Res. Commun. 2010, 395, 104-110.
90. Kim, Y. W.; Zhao, R. J.; Park, S. J.; Lee, J. R.; Cho, I. J.; Yang, C. H.; Kim, S. G.; Kim, S. C. Antiinflammatory effects of liquiritigenin as a consequence of the inhibition of NF-kappaB-dependent iNOS and proinflammatory cytokines production. Br. J. Pharmacol. 2008, 154, 165-173.
91. Kim, Y. W.; Kang, H. E.; Lee, M. G.; Hwang, S. J.; Kim, S. C.; Lee, C. H.; Kim, S. G. Liquiritigenin, a flavonoid aglycone from licorice, has a choleretic effect and the ability to induce hepatic transporters and phase-II enzymes. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296, G372-G381.
92. Kim, Y. W.; Kim, Y. M.; Yang, Y. M.; Kay, H. Y.; Kim, W. D.; Lee, J. W.; Hwang, S. J.; Kim, S. G. Inhibition of LXRalpha-dependent steatosis and oxidative injury by liquiritigenin, a licorice flavonoid, as mediated with Nrf2 activation. Antioxid. Redox Signal. 2010, EPub ahead of print.
93. Kim, Y. W.; Lee, S. M.; Shin, S. M.; Hwang, S. J.; Brooks, J. S.; Kang, H. E.; Lee, M. G.; Kim, S. C.; Kim, S. G. Efficacy of sauchinone as a novel AMPK-activating lignan for preventing iron-induced oxidative stress and liver injury. Free Radic. Biol. Med. 2009, 47, 1082-1092.
94. Min, H. J.; Won, H. Y.; Kim, Y. C.; Sung, S. H.; Byun, M. R.; Hwang, J. H.; Hong, J. H.; Hwang, E. S. Suppression of Th2-driven, allergen-induced airway inflammation by sauchinone. Biochem. Biophys. Res. Commun. 2009, 385, 204-209.
95. Han, K. Y.; Yang, D.; Chang, E. J.; Lee, Y.; Huang, H.; Sung, S. H.; Lee, Z. H.; Kim, Y. C.; Kim, H. H. Inhibition of osteoclast differentiation and bone resorption by sauchinone. Biochem. Pharmacol. 2007, 74, 911-923. (Pubitemid 47212083)
96. Jeong, G. S.; Lee, D. S.; Li, B.; Byun, E.; Kwon, D. Y.; Park, H.; Kim, Y. C. Protective effect of sauchinone by upregulating heme oxygenase-1 via the P38 MAPK and Nrf2/ARE pathways in HepG2 cells. Planta Med. 2010, 76, 41-47.
97. Kensler, T. W.; Helzlsouer, K. J. Oltipraz: Clinical opportunities for cancer chemoprevention. p. J. Cell Biochem. Suppl. 1995, 22, 101-107.
98. Petzer, J. P.; Navamal, M.; Johnson, J. K.; Kwak, M. K.; Kensler, T. W.; Fishbein, J. C. Phase 2 enzyme induction by the major metabolite of oltipraz. Chem. Res. Toxicol. 2003, 16, 1463-1469.
99. Egner, P. A.; Kensler, T. W.; Prestera, T.; Talalay, P.; Libby, A. H.; Joyner, H. H.; Curphey, T. J. Regulation of phase 2 enzyme induction by oltipraz and other dithiolethiones. Carcinogenesis 1994, 15, 177-181. (Pubitemid 24121645)
100. Clapper, M. L. Chemopreventive activity of oltipraz. Pharmacol. Ther. 1998, 78, 17-27.
101. Primiano, T.; Egner, P. A.; Sutter, T. R.; Kelloff, G. J.; Roebuck, B. D.; Kensler, T. W. Intermittent dosing with oltipraz: relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione S-transferases. Cancer Res. 1995, 55, 4319-4324.
102. Iida, K.; Itoh, K.; Kumagai, Y.; Oyasu, R.; Hattori, K.; Kawai, K.; Shimazui, T.; Akaza, H.; Yamamoto, M. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res. 2004, 64, 6424-6431.
103. Auyeung, D. J.; Kessler, F. K.; Ritter, J. K. Mechanism of rat UDP-glucuronosyltransferase 1A6 induction by oltipraz: Evidence for a contribution of the Aryl hydrocarbon receptor pathway. Mol. Pharmacol. 2003, 63, 119-127.
104. Cho, I. J.; Ki, S. H.; Brooks, C., 3rd; Kim, S. G. Role of hepatitis B virus X repression of C/EBPbeta activity in the down-regulation of glutathione S-transferase A2 gene: Implications in other phase II detoxifying enzyme expression. Xenobiotica 2009, 39, 182-192.
105. Chan, L. M.; Lowes, S.; Hirst, B. H. The ABCs of drug transport in intestine and liver: Efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci. 2004, 21, 25-51.
106. Choudhuri, S.; Klaassen, C. D. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int. J. Toxicol. 2006, 25, 231-259.